MONTREAL, QUEBEC -- (MARKET WIRE) -- October 18, 2006 -- Ambrilia Biopharma Inc.(TSX: AMB), a biopharmaceutical company developing innovative therapeutics in the fields of oncology and infectious diseases, announced today a one-for-ten (1:10) consolidation of its common shares. The consolidation is effective on October 13, 2006 and the Company's common shares will begin trading on the Toronto Stock Exchange (TSX) on a consolidated basis at market opening on October 19, 2006.
